Boehringer and Lilly's Trajenta approved for type 2 diabetes in Europe

26 August 2011

Following a positive European Medicines Agency advisory committee recommendation two is months ago, Independent German drugmaker Boehringer Ingelheim and partner US major Eli Lilly (NYSE: LLY) yesterday received marketing authorization from the European Commission for Trajenta (linagliptin) 5mg film-coated tablets for the treatment of adults with type 2 diabetes.

The European Commission has approved linagliptin in combination with metformin and metformin plus sulphonylurea. Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.

The type 2 diabetes drug market is expected to nearly double from $19 billion in 2009 to $36 billion in 2019 in the leading markets of the USA, France, Germany, Italy, Spain, UK and Japan, according to research from advisory firm Decision Resources.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK